TITLE

Treatment of hepatitis C. The 2002 French consensus

AUTHOR(S)
Dhumeaux, D.; marcellin, P.; Lerebours, E.
PUB. DATE
December 2003
SOURCE
Gut;Dec2003, Vol. 52 Issue 12, p1784
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Chronic infection by hepatitis C virus (HCV) affects 170 million people worldwide. In European countries the overall prevalence in adults ranges from 1% to 2%, and more than five million Europeans are thus infected. The high prevalence of HCV infection, together with the risk of severe complications which include cirrhosis and hepatocellular carcinoma, makes this a major public health problem. HCV was discovered more than 10 years ago, and considerable progress has since been made in our knowledge of the virus, its modes of transmission, the natural history of the infection, and also patient management, including specific therapy.
ACCESSION #
12940923

 

Related Articles

  • Global control of hepatitis C: where challenge meets opportunity. Thomas, David L // Nature Medicine;Jul2013, Vol. 19 Issue 7, p850 

    We are entering an important new chapter in the story of hepatitis C virus (HCV) infection. There are clear challenges and opportunities. On the one hand, new HCV infections are still occurring, and an estimated 185 million people are or have previously been infected worldwide. Most HCV-infected...

  • Discovery of Small-Molecule Inhibitors of HCV NS3-4A Protease as Potential Therapeutic Agents against HCV Infection. Shu-Hui Chen; Seng-Lai Tan // Current Medicinal Chemistry;2005, Vol. 12 Issue 20, p2317 

    Chronic infection with hepatitis C virus (HCV) is associated with liver cirrhosis that often leads to hepatic failure and hepatocellular carcinoma (HCC). HCV infection has become a global health threat and the main cause of adult liver transplants in developed nations. Current approved anti-HCV...

  • Hepatitis C virus infection in 2012 and beyond. Abuelhassan, W. // Southern African Journal of Epidemiology & Infection;2012, Vol. 27 Issue 3, p93 

    Hepatitis C virus infection is estimated to affect 150 million people worldwide. A large number of individuals are chronically infected and are at risk of developing chronic liver disease, cirrhosis and hepatocellular carcinoma. Chronic hepatitis C infection causes significant morbidity and...

  • In-vitro antiviral activity of Solanum nigrum against Hepatitis C Virus. Javed, Tariq; Ashfaq, Usman Ali; Riaz, Sana; Rehman, Sidra; Riazuddin, Sheikh // Virology Journal;2011, Vol. 8 Issue 1, p1 

    Background: Hepatitis C is a major health problem causes liver cirrhosis, hepatocellular carcinoma and death. The current treatment of standard interferon in combination with ribavirin, has limited benefits due to emergence of resistant mutations during long-term treatment, adverse side effects...

  • Mangosteen xanthones suppress hepatitis C virus genome replication. Choi, Moonju; Kim, Young-Mi; Lee, Sungjin; Chin, Young-Won; Lee, Choongho // Virus Genes;Oct2014, Vol. 49 Issue 2, p208 

    Hepatitis C virus (HCV) is a hepatotropic single-stranded RNA virus. HCV infection is causally linked with development of liver cirrhosis and hepatocellular carcinoma. Enhanced production of reactive oxygen species by HCV has been implicated to play an important role in HCV-induced pathogenesis....

  • Long Term Follow up of Interferon Treated Chronic HCV Patients in Responders and Non-Responders. Sajjad, Shaimuna Fareeha; Ahmed, Waquaruddin; Arif, Ambreen; Alam, Syed Ejaz // Pakistan Journal of Medical Research;Jul-Sep2015, Vol. 54 Issue 3, p69 

    Background: Interferon with ribavirin is the recommended treatment for chronic hepatitis C with a response rate ranging from 50-80% in different countries. Although sustained response is comparable to clinical cure, but whether interferon therapy slows down the disease process in non-responders...

  • RNA interference-mediated prevention and therapy for hepatocellular carcinoma. Romano, P. R.; McCallus, D. E.; Pachuk, C. J. // Oncogene;6/26/2006, Vol. 25 Issue 27, p3857 

    Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death and is on the increase worldwide. Hepatocellular carcinoma results from chronic liver disease and cirrhosis most commonly associated with chronic hepatitis B (HBV) or hepatitis C (HCV) infection. The highest...

  • Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Barua, Soumitri; Greenwald, Robert; Grebely, Jason; Dore, Gregory J.; Swan, Tracy; Taylor, Lynn E. // Annals of Internal Medicine;8/4/2015, Vol. 163 Issue 3, p215 

    The aim of this study was to systematically evaluate state Medicaid policies for the treatment of hepatitis C virus (HCV) infection with sofosbuvir in the United States. Medicaid reimbursement criteria for sofosbuvir were evaluated in all 50 states and the District of Columbia. The authors...

  • Helicobacter pylori and Hepatitis C Virus Coinfection in Egyptian Patients. El-Masry, Samir; El-Shahat, Mohamed; Badra, Gamal; Aboel-Nour, Mohamed F.; Lotfy, Mahmoud // Journal of Global Infectious Diseases;Jan2010, Vol. 2 Issue 1, p4 

    Introduction: Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide. It has been shown that Helicobacter pylori (H. pylori) plays an important role in chronic gastritis, peptic ulcer disease and gastric malignancies, and its eradication has been...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics